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Abstract
Context—Acute ST-segment elevation myocardial infarction (STEMI) is a leading cause of
morbidity and mortality. In experimental models of MI, erythropoietin reduces infarct size and
improves left ventricular (LV) function.
Objective—To evaluate the safety and efficacy of a single intravenous bolus of epoetin alfa in
patients with STEMI.
Design, Setting, and Patients—Prospective, randomized, double-blind, placebo-controlled
trial with a dose-escalation safety phase and a single-dose (60,000 units of epoetin alfa) efficacy
phase involving 222 patients with STEMI who underwent successful percutaneous coronary
intervention (PCI) as a primary or rescue reperfusion strategy.
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Intervention—Participants were randomly assigned to treatment with intravenous epoetin alfa or
matching saline placebo administered within 4 hours of reperfusion.
Main Outcome Measure—Infarct size, expressed as a percentage of LV mass, assessed by
cardiac magnetic resonance (CMR) imaging 2–6 days after study medication administration.
Results—In the efficacy cohort (n=138), infarct size did not differ between groups at either 2–6
days (15.8±10.3 vs. 15.0±10.0, P=.666) or 12±2 weeks (10.6±8.6 vs. 10.4±7.6, P=.886). Left
ventricular ejection fraction also did not differ between groups at either the early (48.2±9.1 vs.
48.9±8.7, P=.671) or late (52.5±9.3 vs. 52.0±8.8, P=.760) timepoints. In pre-specified analyses of
patients aged ≥70 years (n=21), mean infarct size within the first week was larger in the epoetin
alfa arm than in the placebo group (19.9±9.9 vs.11.7±7.2, P=.026). Patients who received epoetin
alfa had a higher incidence of the composite endpoint of death, myocardial infarction, stroke, or
stent thrombosis (4.0% vs. 0.0%, P=.042), and a higher incidence of serious adverse events
(20.0% vs. 10.3%, P=.052).
Conclusions—In STEMI patients successfully reperfused with primary or rescue PCI, a single
intravenous bolus of epoetin alfa did not reduce infarct size and was associated with higher rates
of adverse cardiovascular events. Furthermore, it may be associated with increased infarct size in
older patients.
Trial Registration—clinicaltrials.gov identifier NCT00378352.
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INTRODUCTION
Despite advances in the management of ST-segment elevation myocardial infarction
(STEMI), it remains a significant cause of morbidity, mortality, and disability,1,2
particularly among older persons.3 Patients who survive STEMI are at risk for developing
infarct expansion (the process of myocardial thinning and infarct zone dilation that begins
soon after coronary occlusion)4 and left ventricular (LV) remodeling (the topographical and
functional changes in the infarct zone and the non-infarcted myocardium).5 Both are
strongly associated with heart failure and death.6 Risk factors for infarct expansion and LV
remodeling include infarct size, extent of apoptosis, anterior location of the infarction,7
severe microvascular obstruction,8 and older age.9 Given the global burden of ischemic
heart disease and heart failure, therapies that limit infarct size and attenuate or reverse LV
remodeling are needed.
Erythropoietin is a 165 amino acid glycoprotein hormone whose production and secretion
are regulated by tissue oxygen levels. Beyond its effects on red cell production,
erythropoietin exhibits pleiotropic effects in cells and tissues, including stimulation of
angiogenesis and protection against apoptosis.10 Further, erythropoietin receptors have been
identified on endothelial cells and cardiomyocytes.11 Preclinical studies have shown that
erythropoietin plays a cardioprotective role in various experimental models of myocardial
ischemia and ischemia-reperfusion.12–17 In these investigations, erythropoietin was
associated with significant reductions in infarct size and improvements in LV function that
were partly attributed to its anti-apoptotic and angiogenic properties.
To determine whether erythropoietin has similar cardioprotective effects in the clinical
setting, we performed the Reduction of Infarct Expansion and Ventricular Remodeling with
Erythropoietin After Large Myocardial Infarction (REVEAL) trial to evaluate the safety and
effect on infarct size of a single intravenous bolus of recombinant human erythropoietin
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(epoetin alfa) in patients with STEMI who have undergone successful primary or rescue
percutaneous coronary intervention (PCI).
METHODS
REVEAL was a multicenter, phase II, randomized, double-blind, placebo-controlled clinical
trial that evaluated the safety and efficacy of a single intravenous bolus of epoetin alfa in
STEMI patients.
Study Design
The design and rationale of REVEAL have been previously published.18 Briefly, the study
consisted of a dose-escalation phase and an efficacy phase (Figure 1). During the dose-
escalation phase, three doses of epoetin alfa were sequentially evaluated: 15,000 (15k),
30,000 (30k), and 60,000 (60k) units (U). These doses were chosen with guidance from the
FDA to balance safety concerns arising from preclinical studies that used relatively high
doses of erythropoietin. Patients were randomly allocated in a 2:1 ratio to each dose of
epoetin alfa or placebo, respectively. Dose escalation was guided by an independent data
and safety monitoring board (DSMB), who reviewed clinical and safety data at two
timepoints for each dose cohort.18 By study design, the highest of the three doses of epoetin
alfa deemed acceptable by the DSMB was used in the efficacy phase, in which participants
were randomly allocated in a 1:1 ratio to epoetin alfa or placebo.
Eligibility Criteria
Study eligibility criteria are listed in Supplementary Table 1. Briefly, patients were eligible
if they had acute STEMI with TIMI flow grade 0–1 in a major epicardial artery or large
branch vessel during index angiography and underwent successful primary or rescue PCI
within 8 hours of onset of ischemic symptoms. To minimize confounding of infarct-size
measurement, patients with a history of LV dysfunction (ejection fraction ≤50%), MI,
coronary artery bypass grafting (CABG), or revascularization in the territory of the culprit
artery were excluded.
Randomization
Eligible patients who provided written informed consent were randomly assigned to epoetin
alfa or matching placebo according to the allocation ratio for each dosing cohort.
Randomization was performed with a fixed-block randomization scheme using a Web-based
application (WebEZ) fully integrated with drug supply management information.
Randomization was stratified according to age (<70 or ≥70 years) and infarct location (left
anterior descending [LAD] or non-LAD coronary artery).
Study Medication
Study medication (epoetin alfa or matching saline placebo) was administered within 4 hours
of successful primary or rescue PCI, defined as time of restoration of ≥TIMI 2 flow in the
IRA. During the initial phase of REVEAL, epoetin alfa and matching placebo were provided
free of charge by Centocor Ortho Biotech Clinical Affairs (Bridgewater, NJ). However,
during the efficacy phase, the company elected to cease providing study medication, and the
study sponsor (the National Institute on Aging [NIA]) purchased active study medication
from Centocor Ortho Biotech and contracted with Florida Biologix (Alachua, FL) to
manufacture matching placebo. All other treatments, including PCI techniques, were at the
discretion of the treating physicians, who were encouraged to adhere to guideline
recommendations for the management of STEMI patients.19
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Cardiac Magnetic Resonance
Patients underwent one cardiac magnetic resonance (CMR) scan 2–6 days after study
medication administration and another at 12±2 weeks. Each CMR examination consisted of
(1) a cine-CMR for assessment of LV volumes (end-systolic volume [LVESV] and end-
diastolic volume [LVEDV]), LV mass (LVM), and LV function quantified by ejection
fraction (LVEF); and (2) a delayed contrast-enhanced CMR for assessment of infarct size.
LVESV, LVEDV, and LVM were indexed to body surface area to yield LVESVi, LVEDVi
and LVMi, respectively. De-identified CMR studies were analyzed at a central core
laboratory (Duke Cardiovascular Magnetic Resonance Center, Durham, NC) by
investigators masked to treatment assignment and clinical outcomes. Details of the imaging
protocol have been published.18
Primary and Secondary Endpoints
The primary efficacy endpoint of the study was infarct size in the territory of the IRA,
expressed as percentage of LV mass and measured by CMR 2–6 days (48–144 hours) after
study medication administration. Secondary endpoints included infarct size, LV remodeling
parameters (LVESVi, LVEDVi, and LVMi) and LV function (LVEF) at 12±2 weeks. We
also examined LVESVi, LVEDVi, LVMi, and LVEF measured at 2–6 days.
Safety endpoints included vital signs, hemoglobin, reticulocyte count, markers of cardiac
injury, and clinical events including death, recurrent MI, unplanned PCI, arterial thrombotic
events (stent thrombosis), venous thrombotic events (deep venous thrombus; pulmonary
embolus), heart failure, and neurologic events (stroke; transient ischemic attack).
Statistical Analysis
The primary comparison was infarct size measured by CMR at 2–6 days after study
medication administration between participants who received the highest dose of epoetin
alfa deemed safe by the DSMB and those who received placebo. The sample size for the
first three patient cohorts in the dose-escalation phase was fixed (n=30/cohort), as agreed
upon by study investigators and the FDA. Because the distribution of infarct size data is
consistently non-normal, the efficacy phase sample size was determined with an empirical
approach that used available infarct size data (mean±SD 19.5±10.6) from studies carefully
matched to the conditions of the present investigation. Power values were estimated by
simulations, which suggested that a sample size of 55 subjects/group in the efficacy phase,
together with 30 subjects from the corresponding dose-escalation phase, would provide
>80% power to detect a difference of ≥20% in infarct size between treatment groups. Thus,
REVEAL continued to accrue patients until 110 participants who received study medication
in the efficacy phase had completed their first CMR scan.
Efficacy data were analyzed on a modified intent-to-treat basis, which excluded one subject
who was randomized but did not receive study medication. The efficacy cohort comprised
all patients from the efficacy phase plus all patients from the 60k-cohort of the dose-
escalation phase who received study medication and underwent CMR 2–6 days later.
Baseline differences between the epoetin alfa and placebo groups were evaluated using the
Fisher mid-P or Fisher exact test for categorical variables and the Wilcoxon rank-sum test
for continuous variables. The primary outcome variable, infarct size expressed as percentage
of LV mass 2–6 days after study medication administration, was compared between groups
using a log-rank test,20 both without and with adjustment for age group (<70 vs. ≥70 years),
IRA location (LAD vs. non-LAD), and enrollment phase. Between-groups comparisons for
all other cardiac variables assessed by CMR were performed with ANOVA for unadjusted
analyses and with ANCOVA for adjusted analyses. The adjusted analyses controlled for age
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group, IRA location, and enrollment phase. Adjustment for enrollment phase was performed
to control for implicit differences that may exist between patients recruited in the dose-
escalation phase and patients recruited in the efficacy phase. For cardiac variables measured
at 12±2 weeks, the adjusted models also controlled for values of the same variables obtained
on earlier CMR (2–6 days after study medication administration).
Primary and secondary endpoints were further analyzed within the prespecified subgroups of
patient age (<70 vs. ≥70 years) and IRA location (LAD vs. non-LAD).
Safety data were analyzed on an as-treated basis. The safety cohort comprised all patients
who received study medication. Composite safety endpoints were added to the analysis plan
at the suggestion of the DSMB and were compared using the Fisher mid-P test.
One prespecified interim test of efficacy was performed, using the Haybittle-Peto rule.21
Due to rounding, the interim analysis did not result in a penalty for the final alpha level.
A two-sided alpha level of 0.05 was considered statistically significant. P values were not
adjusted for multiple comparisons. All analyses were performed in SAS version 9.2 (SAS
Institute Inc., Cary, NC).
RESULTS
Between October of 2006 and November of 2009, 222 participants at 22 U.S. sites were
randomized and received study medication. Of these, 189 had a CMR scan performed within
2–6 days after study drug administration: 24 in the 15k cohort; 27 in the 30k cohort; and 138
in the 60k efficacy cohort. Most participants in the efficacy cohort (n=124; 89.9%)
underwent follow-up CMR at 12±2 weeks.
The respective baseline clinical characteristics of the total and efficacy cohorts, stratified
according to treatment assignment, are summarized in Table 1. The active medication and
placebo groups were well matched, although the former had a significantly lower prevalence
of diabetes mellitus, less use of rescue PCI, and a longer time from randomization until
study drug administration.
Efficacy Analyses
Cardiac variables assessed by CMR in the efficacy cohort are shown in Table 2. The
primary study endpoint (infarct size at 2–6 days after study medication administration) did
not differ between the epoetin alfa and placebo groups in either the unadjusted (Figure 2A)
or adjusted analysis, which controlled for age group, IRA location, and enrollment phase.
Infarct size at 12±2 weeks did not differ between groups in either unadjusted (Figure 2A) or
adjusted analyses. Adjusting for baseline clinical characteristics that differed between
groups did not affect these findings. As with infarct size, infarct mass did not differ between
groups at either timepoint.
LVEF, LVESVi, and LVEDVi did not differ between groups in the unadjusted analysis at
either timepoint (Table 2); however, at 12±2 weeks, the adjusted analyses (which controlled
for values of LVESVi and LVEDVi on initial CMR) showed that LVESVi and LVEDVi
were respectively 8.1% (P=.036) and 7.2% (P=.014) larger in the epoetin alfa group than in
the placebo group. Thus, in post hoc comparisons to the placebo group, the epoetin alfa
group had a smaller decrease in LVESVi from first to second CMR scan, but a greater
increase in LVEDVi.
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LVMi was the only endpoint that differed significantly between groups in the unadjusted
analysis. On first CMR scan, the mean LVMi was 6.7% higher in the epoetin alfa group than
in the placebo group (unadjusted P=.040, adjusted P=.028). This difference persisted at 12±2
weeks, but was due to the difference in LVMi on the first CMR study, as the change in
LVMi from first to second CMR did not differ between groups.
Subgroup Analyses
Neither infarct size at 2–6 days or at 12±2 weeks differed between treatment groups
according to IRA location in either the unadjusted or adjusted analysis.
The interaction between treatment assignment and age group trended toward significance
(P=.084), suggesting that age group may modify the effect of epoetin alfa on infarct size.
Infarct size did not differ between groups among patients <70 years of age (Figure 2B).
However, among patients ≥70 years (n=21), infarct size at 2–6 days was 41.2% higher in the
epoetin alfa group than in the placebo group (19.9±9.9 vs. 11.7±7.2, unadjusted P=.026,
adjusted P=.019) (Figure 2C). These results were unchanged when analyses were further
adjusted for presence of diabetes mellitus—the only characteristic that significantly differed
between the two groups (prevalence of 9.1% and 54.4% in the epoetin alfa and placebo
groups, respectively). Among patients ≥70 years, infarct size at 12±2 weeks remained 40.0%
higher in the epoetin alfa group than in the placebo group (15.0±10.0 vs. 9.0±6.5, unadjusted
P=.121), mainly due to the difference in infarct size on the first CMR (adjusted P=.066 when
controlling for IRA location and enrollment phase; adjusted P=.875 when controlling for
those plus the initial CMR value of infarct size).
Safety Analyses
Adverse events were reported in 55.2% of participants who received epoetin alfa and 41.2%
of those who received placebo (P=.037). Serious adverse events were reported in 20.0% of
subjects who received epoetin alfa, and 10.3% of those who received placebo (P=.052)
(Table 3). The composite outcome of death, MI, stroke, or stent thrombosis occurred in five
(4.0%) participants who received epoetin alfa but in none of those who received placebo
(P=.042). Description of these clinical events can be found in the online supplement.
There were no clinically meaningful differences between groups in hemoglobin levels,
reticulocyte counts, or blood pressure at the various timepoints assessed after administration
of study medication (data not shown), likely reflecting the fact that only a single infusion of
epoetin alfa was administered. Similarly, there were no clinically meaningful differences
between groups in the changes in the levels of these variables from baseline or from the
preceding timepoint.
DISCUSSION
In the REVEAL Trial, a single bolus of intravenous epoetin alfa in STEMI patients who
underwent successful primary or rescue PCI failed to demonstrate a benefit, was associated
with increased infarct size in older patients, and was associated with more cardiovascular
adverse events, including stent thrombosis. Clinical interest in the use of erythropoietin as a
cardioprotective agent emanated from a growing body of experimental evidence showing
that erythropoietin’s non-erythropoietic effects include anti-inflammatory, anti-apoptotic,
and angiogenic properties.10,22 In preclinical models, erythropoietin promotes
neovascularization and induces mobilization of endothelial progenitor cells from bone
marrow.23 In animal models of ischemic myocardial injury, erythropoietin was shown to
reduce apoptotic cells,12,17 diminish cardiomyocyte loss,16 improve functional recovery,14
decrease infarct size16,17 and attenuate infarct expansion.17
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Previous clinical studies evaluating the effects of erythropoietin on infarct size have yielded
conflicting results. In four of these studies, infarct size was indirectly estimated from serial
measurements of enzymatic markers of cardiac injury. In the HEBE III trial, a single dose of
erythropoietin (60,000 U) within 3 hours of primary PCI in STEMI patients reduced
enzymatic infarct size by 6.7% (P=.06) but did not improve LVEF at 6 weeks.26 In a small
pilot study, a single dose of erythropoietin (33,000 U) reduced enzymatic infarct size by
30%.27 However, in two other trials (one in non-STEMI patients and one in STEMI patients
treated with fibrinolysis), a single dose of erythropoietin (40,000 U) did not reduce
enzymatic infarct size.24,25
In the pilot study mentioned above,27 erythropoietin did not affect infarct size at 6 months as
assessed by contrast-enhanced CMR, a powerful, validated tool that allows accurate and
reproducible measurement of infarct size.28,29 Using CMR, the REVIVAL-3 study found
that three daily doses of erythropoietin (33,000 U each) did not reduce infarct size at 5 days
or 6 months30; 6-month LVEF also remained unimproved.
Taken together with the REVEAL trial, these results indicate that no clinical study to date
has shown any beneficial effect of erythropoietin on CMR-measured infarct size.
Furthermore, the results in the subgroup of participants ≥70 years in REVEAL suggest that
erythropoietin may adversely affect infarct size in this high-risk population. Although this
concerning finding should be interpreted with caution due to the small number of older
patients enrolled in REVEAL and the lack of multiplicity adjustment in the analyses, it
suggests the need for added vigilance before enrolling older patients in any future trial
evaluating erythropoietin in the setting of MI.
In the small (N=30) pilot study that reported a 30% reduction in enzymatic infarct size with
erythropoietin, the erythropoietin group had a greater decrease in LVESV than the placebo
group, and a similar increase in LVEDV.27 Our larger study failed to replicate these
observations. Instead, the epoetin alfa arm in REVEAL showed a smaller decrease in
LVESVi and a larger increase in LVEDVi than the placebo group, suggesting a greater
reliance on the Frank-Starling mechanism to augment stroke volume (data not shown). Thus,
administration of erythropoietin may be associated with adverse LV remodeling at 3 months.
In REVEAL, we also found a significantly increased risk of death, recurrent MI, stroke, or
stent thrombosis with erythropoietin, suggesting an increased thrombotic risk with
erythropoietin in STEMI patients. This is consistent with other studies involving
erythropoietin in non-cardiac populations.31–33 Chronic administration of erythropoietin can
lead to increases in vasoconstriction, blood pressure, blood viscosity,34 and thrombotic
risk.35 Some previous studies in patients with MI did not detect an increased risk of adverse
events with erythropoietin,25,27,36 and the HEBE III trial even reported a lower risk of major
adverse cardiovascular outcomes in patients receiving erythropoietin.24 On the other hand,
the REVIVAL-3 observed an increased risk of death, recurrent MI, stroke, or target vessel
revascularization in patients who received erythropoietin.30
Reconciling Animal and Clinical Studies
It is conceivable that the effects of erythropoietin differ across species. For example,
although erythropoietin reduced infarct size in a rodent model of coronary occlusion,17 it
failed to do so in a porcine model.37 Moreover, the average infarct size in REVEAL
(approximately 15%–16%) was smaller than infarct sizes reported in animal studies.
However, the average infarct size in the REVIVAL-3 study was approximately 27%–28%29
and erythropoietin still was not effective in reducing infarct size. In addition, the doses of
erythropoietin used in animal studies (3000–5000 U/kg) were generally higher than those
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used in clinical studies. However, the cardioprotective effects of erythropoietin have been
demonstrated at doses as low as 150 U/kg in rodents.38
Importantly, animal studies indicate that there is a therapeutic window of time beyond which
the tissue-protective effects of erythropoietin are attenuated; further, the duration of this
window is directly related to erythropoietin dose.31 For example, in a rodent model of
coronary ligation, the benefits of erythropoietin at 3000 U/kg can still be observed when
administration is delayed up to 12 (but not 24) hours after ischemic injury; whereas at 150
U/kg, these benefits are observed only when erythropoietin is administered within 4 (but not
8) hours of ischemic injury. Further, in a rodent model of ischemia (2 hours)-reperfusion
(wherein infarct size is expected to be smaller than that achieved with permanent coronary
ligation), an erythropoietin dose of 3000 U/kg was effective in reducing infarct size if
administered at time of reperfusion, but not if infused 2 hours later (Talan M, unpublished
data). In REVEAL, erythropoietin was infused, on average, >6 hours after symptom onset.
Thus, we cannot exclude the possibility that administration of erythropoietin in our study
occurred beyond the therapeutic window. We did not observe an association between infarct
size and time from symptom onset to time of erythropoietin administration (data not shown).
In addition, the REVIVAL-3 trial30 did not observe an effect on infarct size although
erythropoietin was administered at time of PCI. Whether earlier administration of
erythropoietin might reveal cardioprotective properties in humans remains to be determined.
In summary, a single bolus of 60,000 U of epoetin alfa in STEMI patients within 4 hours
following successful PCI does not reduce infarct size and may increase infarct size among
patients aged ≥70 years. Epoetin alfa was associated with unfavorable remodeling and
higher risk of adverse clinical events. Whether very early administration of erythropoietin
after symptom onset might reveal cardioprotective properties in humans remains to be
determined.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix
Description of clinical events in the composite outcome
One participant, a man aged 90 years enrolled in the lowest-dose (15k) cohort who received
active study medication, developed acute renal failure and subsequently died of heart failure
approximately 2 weeks after enrollment. One patient who received 15k of epoetin alfa had
an ischemic stroke 7 days later. Three patients developed stent thrombosis, all of whom
received epoetin alfa. Stent thrombosis was acute (7 hours after administration of study
medication) in one participant who received the 60k dose of epoetin alfa, and subacute (5
days and 4 days after administration of study medication, respectively) in two participants
who received the 30k and 60k doses of epoetin alfa, respectively. The latter two sustained a
recurrent MI as a result of stent thrombosis. Thus, five (4.0%) participants who received
active study medication sustained the composite outcome of death, MI, stroke, or stent
thrombosis, while no participants who received placebo sustained that outcome (P=.042).
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Figure 1.
REVEAL study flow.
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Figure 2.
Comparison of infarct size, expressed as percentage of LV mass, between epoetin alfa and
placebo groups in the overall efficacy cohort (A), in patients <70 years of age (B), and in
patients ≥70 years of age (C). *P=.026. Boxes extend to 25th and 75th percentiles. Whiskers
extend to minimum and maximum values. Mean values are represented by a dot within the
box; medians are represented by a horizontal line within the box.
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Table 1
Baseline Characteristics of Study Patients
Total Cohort (n=222) Efficacy Cohort (n=138)
Epoetin alfa Placebo Epoetin alfa Placebo
Demographics
 n (%)a 123 (55.4) 99 (44.6) 68 (49.3) 70 (50.7)
 Age, y 56.8 (12.4) 58.8 (12.5) 55.6 (12.6) 57.4 (11.9)
 Female sex, n (%) 23 (18.7) 21 (21.2) 7 (10.3) 14 (20.0)
 White race, n (%) 104 (84.6) 81 (81.8) 59 (86.8) 61 (87.1)
 Weight, kg 89.9 (18.6)b 87.4 (16.0) 89.3 (16.8) 87.1 (15.3)
 Height, cm 174.4 (9.2)b 173.2 (9.7) 174.6 (8.3) 173.7 (9.5)
Comorbid conditions
 Diabetes, n (%) 14 (11.4) 25 (25.3)c 6 (8.8) 17 (24.3)c
 Hypertension, n (%) 58 (47.2) 53 (53.5) 28 (41.2) 34 (48.6)
 Hyperlipidemia, n (%) 50 (40.7) 43 (44.8) 24 (35.3) 30 (43.5)
 Current smoker 47 (38.8)d 42 (42.4) 27 (40.3)e 32 (45.7)
Baseline medications, n (%)
 Aspirin 110 (90.2) 93 (93.9) 62 (91.2) 64 (91.4)
 Clopidogrel 118 (96.7) 94 (95.9) 66 (97.1) 66 (94.3)
 GP IIb/IIIa inhibitor 88 (72.7) 71 (71.7) 46 (67.6) 45 (64.3)
 Heparinf 108 (87.9) 86 (86.9) 60 (88.2) 60 (85.7)
 Thrombolytic therapy 9 (7.4) 8 (8.1) 3 (4.4) 6 (8.6)
Patient subgroups
 Age category
  <70 y, n (%) 103 (83.7) 81 (81.8) 57 (83.8) 59 (84.3)
  ≥70 y, n (%) 20 (16.3) 18 (18.2) 11 (16.2) 11 (15.7)
 Infarct-related artery
  Non-anterior, n (%) 89 (72.4) 72 (72.7) 48 (70.6) 51 (72.9)
  Anterior, n (%) 34 (27.6) 27 (27.3) 20 (29.4) 19 (27.1)
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Total Cohort (n=222) Efficacy Cohort (n=138)
Epoetin alfa Placebo Epoetin alfa Placebo
Clinical characteristics
 Type of PCI
  Primary, n (%) 110 (89.4) 82 (82.8)c 64 (94.1) 55 (78.6)c
  Rescue, n (%) 13 (10.6) 17 (17.2) 4 (5.9) 15 (21.4)
 Killip class I, n (%)g 115 (100) 91 (94.8) c 62 (100) 64 (95.5)
 Heart rate, BPM 77.4 (16.1) 76.5 (13.6) 77.0 (14.5) 75.6 (13.2)
 Systolic BP, mm HG 129.5 (17.9) 126.5(18.8) 132.8 (18.1) 126.7 (19.3)
 Diastolic BP, mm HG 78.4 (12.7) 76.0 (13.7) 79.9 (12.2) 76.8 (13.4)
 Time from symptom onset to restoration of TIMI 2–3 flow, min 207.5 (106.8) 208.3 (105.7) 210.9 (98.3) 201.9 (111.2)
 Time from TIMI flow restoration to study drug administration, min 176.3 (77.3) 183.0 (74.1) 172.4 (75.0) 175.5 (75.3)
 Time from randomization to study drug administration, min 47.5 (48.0)h 39.9 (32.9)c 47.9 (32.6)i 39.6 (34.6)c
Continuous variables are given as mean (SD). Abbreviations: PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial
infarction.
aValues given according to treatment assignment.
b
Total n=122.
cP<.05 for between-group comparison.
d
Total n=121.
e
Total n=67.
f
Includes both unfractionated and low-molecular-weight heparin.
g
Total cohort: epoetin alfa, total n=115; placebo, total n=96. Efficacy cohort: epoetin alfa, total n=62; placebo, total n=67.
h
Total n=122.
i
Total n=67.
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Table 3
Clinical Adverse Events, Total Cohort (N = 222)
Epoetin alfa (n = 125)a Placebo (n = 97)a P Value
Death 1 (0.8) 0 .719
Myocardial infarctionb 2 (1.6) 0 .348
Unstaged PCI 6 (4.8) 0 .022
CABG 0 1 (1.0) .219
Stroke 1 (0.8) 0 .719
DVT/pulmonary embolism 0 0 –
New/worsening heart failure 5 (4.0) 2 (2.1) .358
Stent thrombosis 3 (2.4) 0 .170
LV thrombus 3 (2.4) 2 (2.1) .828
Composite events
 Any adverse event 69 (55.2) 40 (41.2) .037
 Any serious adverse event 25 (20.0) 10 (10.3) .052
 Death/MI/stroke/stent thrombosis 5 (4.0) 0 .042
 Death/MI/stroke 4 (3.2) 0 .084
All values given as n (%).
aNumber of participants for epoetin alfa and placebo arms for total cohort given according to treatment received.
b
Does not include index event. Adverse events include events occurring during the period between randomization and discharge or day 7,
whichever comes first. Serious adverse events include events occurring during the period between randomization and 12± 2 weeks.
Abbreviations: CABG, coronary artery bypass graft; DVT, deep venous thrombosis; LV, left ventricle; MI, myocardial infarction; PCI,
percutaneous coronary intervention.
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